Driving Pressure-guided Tidal Volume Ventilation in the Acute Respiratory Distress Syndrome: a Prospective, Multicenter, Randomized, Controlled, Open-label, Phase III Trial
| Registry | NCT06322758, acronym DRIVENT |
|---|---|
| Status | Not yet recruiting |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: none, treatment |
| Enrollment | 750 (Estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris (Other) |
| Conditions | Acute Respiratory Distress Syndrome ARDS |
| Interventions | Tidal volume customization in the acute respiratory distress syndrome (Other) |
| Dates | start 2024-09-01 (estimated), primary completion 2026-10-01 (estimated), completion 2026-12-01 (estimated), first posted 2024-03-21, last updated 2024-03-26 |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Acute Respiratory Distress Syndrome ARDS All trials of Tidal volume customization in the acute respiratory distress syndrome
Acute respiratory distress syndrome (ARDS) is associated with high mortality, some of which can be attributed to ventilator-induced lung injury (VILI) when artificial ventilation is not customized to the severity of lung injury. As ARDS is characterized by a decrease in aerated lung volume, reducing tidal volume (VT) from 12 to 6 mL/kg of predicted body weight (PBW) was shown to improve survival more than 20 years ago. Since then, the VT has been normalized to the PBW, meaning to the theoretical lung size (before the disease), rather than tailored to the severity of lung injury, i.e., to the size of aerated lung volume. During ARDS, the aerated lung volume is correlated to the respiratory system compliance (Crs). The driving pressure (ΔP), defined as the difference between the plateau pressure and the positive end expiratory pressure, represents the ratio between the VT and the Crs. Therefore, the ΔP normalizes the VT to a surrogate of the aerated lung available for ventilation of the diseased lung, rather than to the theoretical lung size of the healthy lung, and thus represents more accurately the actual strain applied to the lungs. In a post hoc analysis of 9 randomized controlled trials, Amato et al. found that higher ΔP was a better predictor of mortality than higher VT, with an increased risk of death when the ΔP > 14 cm H2O. These findings have been confirmed in subsequent meta-analysis and large-scale observational data. In a prospective study including 50 patients, the investigators showed that a ΔPguided ventilation strategy targeting a ΔP between 12 and 14 cm H2O significantly reduced the mechanical power, a surrogate for the risk of VILI, compared to a conventional PBW-guided ventilation. In the present study, the investigators hypothesize that the physiological individualization of ventilation (ΔP-guided VT) may improve the outcome of patients with ARDS compared to traditional anthropometrical adjustment (PBW-guided VT)
| Arm | Type | Interventions | Description |
|---|---|---|---|
| ΔP-guided VT group | Experimental | Other: Tidal volume customization in the acute respiratory distress syndrome | During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target |
| PBW-guided VT group | Active comparator | Other: Tidal volume customization in the acute respiratory distress syndrome | The VT will be kept at 6 mL/kg of PBW. If the plateau pressure threshold is reached (30 cm H2O), the VT will be decreased down to a minimal value of 4 mL/kg of PBW. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Age > 18 years * Invasive mechanical ventilation * Criteria for ARDS according to Berlin definition: * Bilateral infiltrates not fully explained by effusions, lobar/lung collapse, or nodules; * PaO2/FiO2 of 300 or less measured with a PEEP of at least 5 cm H2O * Respiratory failure not fully explained by cardiac failure or fluid overload These criteria must be observed for less than 72h * Affiliation to the social security system * Written consent obtained from the patients (from a support person, family member or a close relative if the patient is not able to expressing and sign consent) or inclusion without initial consent in case of emergency, if the patient is not able to express his/her consent and in the absence of support person, family member or a close relative Exclusion Criteria: * Known pregnancy * Lung transplantation * Evident significant decrease in chest wall compliance (e.g., abdominal compartment syndrome) * Moribund patient not expected to survive 24 hours * Presence of an advanced directive to withhold life-sustaining treatment or decision to withhold life-sustaining treatment * Chronic respiratory disease requiring home oxygen therapy or ventilation * ECMO before inclusion * Pneumothorax * Enrollment in an interventional ARDS trial with direct impact on VT * Subject deprived of freedom, subject under a legal protective measure (guardianship/curatorship)